|
Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar |
Speakers' Bureau - Bayer; Dendreon; Janssen |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline; Lilly; Noria Pharma Solutions |
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Progenics; Sanofi |
Research Funding - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst) |
Expert Testimony - Sanofi |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst) |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Sanofi; Steba Biotech; Takeda |
Speakers' Bureau - Amgen; Janssen |
Research Funding - Ferring (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi |
|
|
Honoraria - Advanced Accelerator Applications; Amgen; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sotio; Tolmar |
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sotio; Tolmar |
Speakers' Bureau - Janssen Oncology |
Travel, Accommodations, Expenses - Amgen Astellas BioPharma; Bayer Schering Pharma; Bristol-Myers Squibb; Ferring; Janssen Oncology; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Tolmar |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
|
|
Stock and Other Ownership Interests - CTI (I) |
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Hinova Pharmaceuticals; Janssen; Myriad Genetics; Orion; Tolmar |
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Dendreon (Inst); Emergent BioSolutions (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Ferring; Genentech; Hinova Pharmaceuticals; Menarini; Myriad Genetics; Orion; Pfizer |